Bliss GVS Pharma Ltd (BLISSGVS) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Bliss GVS Pharma

Shukra Pharma.

Amrutanjan Healt

Syncom Formul.

Windlas Biotech

Jagsonpal Pharma

Novartis India

Bajaj Healthcare

Sigachi Indust.

Hester Bios

Beta Drugs Ltd

Why is Bliss GVS Pharma Ltd ?

Company has a low Debt to Equity ratio (avg) at 0 times

Poor long term growth as Net Sales has grown by an annual rate of 9.41% and Operating profit at 1.49% over the last 5 years

Flat results in Sep 25

INTEREST(Latest six months) At Rs 8.51 cr has Grown at 208.33%
PBT LESS OI(Q) At Rs 20.45 cr has Fallen at -33.32%
DEBTORS TURNOVER RATIO(HY) Lowest at 1.75 times

With ROE of 9.7, it has a Fair valuation with a 1.6 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 6.41%, its profits have risen by 18.4% ; the PEG ratio of the company is 0.9

Falling Participation by Institutional Investors

Institutional investors have decreased their stake by -0.53% over the previous quarter and collectively hold 19.2% of the company
These investors have better capability and resources to analyse fundamentals of companies than most retail investors

Market Beating performance in long term as well as near term

Along with generating 6.41% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Bliss GVS Pharma should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Bliss GVS Pharma for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Bliss GVS Pharma

5.95%

0.12

55.71%

Sensex

4.78%

0.40

11.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.41%

EBIT Growth (5y)

1.49%

EBIT to Interest (avg)

13.36

Debt to EBITDA (avg)

0.78

Net Debt to Equity (avg)

-0.13

Sales to Capital Employed (avg)

0.73

Tax Ratio

29.46%

Dividend Payout Ratio

6.94%

Pledged Shares

Institutional Holding

19.20%

ROCE (avg)

12.16%

ROE (avg)

9.42%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.58

EV to EBIT

17.89

EV to EBITDA

13.26

EV to Capital Employed

1.67

EV to Sales

1.91

PEG Ratio

0.92

Dividend Yield

0.29%

ROCE (Latest)

9.34%

ROE (Latest)

9.68%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

PAT(Latest six months)

At Rs 70.29 cr has Grown at 56.34%

ROCE(HY)

Highest at 14.76%

DEBT-EQUITY RATIO(HY)

Lowest at 0.05 times

NET SALES(Q)

Highest at Rs 244.40 cr

-13What is not working for the Company

INTEREST(Latest six months)

At Rs 8.51 cr has Grown at 208.33%

PBT LESS OI(Q)

At Rs 20.45 cr has Fallen at -33.32%

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.75 times

NON-OPERATING INCOME(Q)

is 49.67 % of Profit Before Tax (PBT

Loading Valuation Snapshot...

Here's what is working for Bliss GVS Pharma

Profit After Tax (PAT) - Latest six months

At Rs 70.29 cr has Grown at 56.34%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is very positive

PAT (Rs Cr)

Debt-Equity Ratio - Half Yearly

Lowest at 0.05 times and Fallen

each half year in the last five half yearly periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales - Quarterly

Highest at Rs 244.40 cr

in the last five quarters

MOJO Watch

Near term sales trend is positive

Net Sales (Rs Cr)

Here's what is not working for Bliss GVS Pharma

Interest - Latest six months

At Rs 8.51 cr has Grown at 208.33%

over previous Half yearly period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 20.45 cr has Fallen at -33.32%

Year on Year (YoY)

MOJO Watch

Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Debtors Turnover Ratio- Half Yearly

Lowest at 1.75 times and Fallen

each half year in the last five half yearly periods

MOJO Watch

Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio

Non Operating Income - Quarterly

is 49.67 % of Profit Before Tax (PBT)

MOJO Watch

The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT